STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability

Approximately 30% of human cancers harbor oncogenic gain-of-function mutations in KRAS. Despite interest in KRAS as a therapeutic target, direct blockade of KRAS function with small molecules has yet to be demonstrated. Based on experiments that lower mRNA levels of protein kinases, KRAS-dependent c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Luo, Tuoping, Masson, Kristina, Jaffe, Jacob D., Silkworth, Whitney, Ross, Nathan T., Scherer, Christina A., Scholl, Claudia, Fröhling, Stefan, Carr, Steven A., Stern, Andrew M., Schreiber, Stuart L., Golub, Todd R.
Formato: Artigo
Idioma:Inglês
Publicado em: National Academy of Sciences 2012
Assuntos:
Biological Sciences
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3286931/
https://ncbi.nlm.nih.gov/pubmed/22323609
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1120589109
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados